Siemens Healthineers Releases Test Kit for Coronavirus COVID-197 Apr, 2020
Siemens Healthineers announced on Apr 02, 2020 the availability of its molecular Fast Track Diagnostics (FTD) SARS-CoV-2 Assay test kit used to aid in the diagnosis of infection by the SARS-CoV-2 virus that causes the COVID-19 disease. Test kits are already being shipped within the European Union for research use only (RUO) to expedite availability while the company continues to pursue Emergency Use Assessment and Listing (EUAL) from the World Health Organization (WHO) for cli...
IRB Barcelona collaborates with Amazon in the development of a computational tool to speed up the search for drugs against COVID-196 Apr, 2020
There are currently more than 10,000 scientific articles related to coronavirus infections. In fact, in recent weeks, research to combat COVID-19 has accelerated, and more than 4,000 new academic papers have been published on potential vaccines, therapies, and treatments. Processing this volume of information manually would be unmanageable to be able to advance this urgently needed research fast enough. IRB Barcelona’s Structural Bioinformatics and Network Biology Laboratory, led by I...
Daily coronavirus deaths continue downward trend in Spain, with 674 in the last 24 hours6 Apr, 2020
The downward trend of daily deaths from the coronavirus continued on Sunday, with the latest number falling to 674, according to official figures supplied by the Health Ministry. This marks a fall of 135 compared to Saturday, which saw 809. Sunday’s figure is the lowest seen in 10 days. The highest total so far was reported on April 2, with 950 fatalities from Covid-19 in a 24-hour period.
The total number of deaths in Spain from the coronavirus now stands at 12,418,...
FDA Continues to Accelerate Development of Novel Therapies for COVID-191 Apr, 2020
As part of the Trump Administration’s all-hands-on-deck approach across public, academic and private sectors to combat the COVID-19 pandemic, the U.S. Food and Drug Administration stood up a new program to expedite the development of potentially safe and effective life-saving treatments. The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, while at the same ...
Oxford firm to screen 15,000 drugs in search for coronavirus cure1 Apr, 2020Via The Guardian, Julia Kollewe write: Oxford firm to screen 15,000 drugs in search for coronavirus cureExscientia to use AI to hunt through compounds which have passed human trials
An Oxford-based firm that uses artificial intelligence to develop new medicines has teamed up with a UK national science facility to screen more than 15,000 drugs for their effectiveness as a treatment for Covid-19.
Exscientia, a spinoff company from the University of Dundee that is now based in Oxf...
The U.S. Just Signed A $450 Million Coronavirus Vaccine Contract With Johnson & Johnson31 Mar, 2020
The Trump administration is spending nearly half a billion dollars on one company in the race to find a coronavirus vaccine.
That’s according to a $456 million order with Johnson & Johnson’s Pharmaceuticals arm Janssen, which specified a “new vaccine asset for 2019 Novel Coronavirus (COVID-19),” Forbes found. It’s the largest reported amount spent on a vaccine project to date, even though the pharma giant hasn’t yet started any clinical trials as other fir...
MIT ties up with Italian design company for Covid-19 ICUs30 Mar, 2020
Architects have designed mobile hospitals in order to provide intensive care to the patients of coronavirus, which can increase their chance of survival.
An Italian design company has teamed up with the Massachusetts Institute of Technology to create prefabricated intensive care units (ICUs), to deal with escalating numbers of coronavirus patients around the world.
Click here for reference
MIT works on the deployment of an open-source and low-cost ventilator30 Mar, 2020Via MIT NEWS, David L. Chandler write: MIT-based team works on rapid deployment of open-source, low-cost ventilator
Clinical and design considerations will be published online; goal is to support rapid scale-up of device production to alleviate hospital shortages.
One of the most pressing shortages facing hospitals during the Covid-19 emergency is a lack of ventilators. These machines can keep patients breathing when they no longer can on their own, and they can cost around $30,000...
FDA authorizes 15-minute coronavirus test29 Mar, 2020Federal health officials on Friday approved a coronavirus test that can provide results in less than 15 minutes, using the same technology that powers some rapid flu tests.
Teased by Vice President Mike Pence in a Thursday press briefing, the new diagnostic test could accelerate testing in the United States, allowing for rapid results in doctors' offices. But shortages of critical equipment used to collect patient specimens, like masks and swabs, could blunt its impact.
The US Food ...
The coronavirus isn’t mutating quickly, suggesting a vaccine would offer lasting protection28 Mar, 2020The coronavirus is not mutating significantly as it circulates through the human population, according to scientists who are closely studying the novel pathogen’s genetic code. That relative stability suggests the virus is less likely to become more or less dangerous as it spreads, and represents encouraging news for researchers hoping to create a long-lasting vaccine.
Scientists now are studying more than 1,000 different samples of the virus, Peter Thielen, a molecular geneticis...
Prisma Health introduces an open source Ventilator Expansion device!27 Mar, 2020VESper™ is a new device that allows one ventilator to support up to four patients under emergency use authorization by the FDA. Hospitals can apply to receive the free source code and printing specifications for the device.
VESper™ is a unique ventilator expansion device that allows a single ventilator to support up to four patients during times of acute equipment shortages such as the current COVID-19 pandemic.
Produced using 3D printing technology, the device is d...
Spain's Grifols to Test Plasma Therapy for COVID-19 With U.S. FDA26 Mar, 2020
Spain's Grifols has agreed to work with the U.S. Food and Drug Administration and other agencies to gather plasma from patients who have recovered from COVID-19 and test potential therapies for the disease, the pharmaceutical firm said on Wednesday.
The plasma will be processed to produce hyperimmune immunoglobins, which will then be put to pre-clinical and clinical tests to see if they can help treat the disease, Grifols said in a statement.
COVID-19 is caused by the corona...